Dear members of the SB,
As part of the strategy to resolve the worldwide shortage of thrombolytic therapy, the BSC has been informed that Boehringer-Ingelheim will temporarily produce Actilyse vials with latex plugs that could also contain traces of Gentamycine. These vials could be encountered in your local hospital from the end of October onward (and will likely be produced for several months).
BI states that boxes containing vials with latex plugs and vials that could contain traces of Gentamycine will be clearly labeled by stickers (see photograph). These vials should never be administered to patients with a latex/rubber sensitivity or sensitivity to Gentamycine.